Whitney Townsend

Whitney Townsend

Auto-generated profile, based on publicly available information

Whitney Townsend

Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2015 in Circulation
Verified
Journal Article
Closed access
PDF file
JPJohn D. Piette
John D. Piette
JLJustin List
Justin List
GRGurpreet K. Rana
Gurpreet K. Rana
WTWhitney Townsend
Whitney Townsend
DSDana Striplin
Dana Striplin
MHMichele Heisler
Michele Heisler
We examined evidence on whether mobile health (mHealth) tools, including interactive voice response calls, short message service, or text messaging, and smartphones, can improve lifestyle behaviors and management related to cardiovascular diseases throughout the world. We conducted a state-of-the-art review and literature synthesis of peer-reviewed and gray literature published since 2004. The review prioritized randomized trials and studies focused on cardiovascular diseases and risk factors, but included other reports when they represented the best available evidence. The search emphasized reports on the potential benefits of mHealth interventions implemented in low- and middle-income countries. Interactive voice response and short message service interventions can improve cardiovascular preventive care in developed countries by addressing risk factors including weight, smoking, and physical activity. Interactive voice response and short message service–based interventions for cardiovascular disease management also have shown benefits with respect to hypertension management, hospital readmissions, and diabetic glycemic control. Multimodal interventions including Web-based communication with clinicians and mHealth-enabled clinical monitoring with feedback also have shown benefits. The evidence regarding the potential benefits of interventions using smartphones and social media is still developing. Studies of mHealth interventions have been conducted in >30 low- and middle-income countries, and evidence to date suggests that programs are feasible and may improve medication adherence and disease outcomes. Emerging evidence suggests that mHealth interventions may improve cardiovascular-related lifestyle behaviors and disease management. Next-generation mHealth programs developed worldwide should be based on evidence-based behavioral theories and incorporate advances in artificial intelligence for adapting systems automatically to patients’ unique and changing needs.

10 September 2013 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
DKDinesh Khanna
Dinesh Khanna
HGHeather Gladue
Heather Gladue
RCRichard Channick
Richard Channick
LCLorinda Chung
Lorinda Chung
ODOliver Distler
Oliver Distler
VMVallerie V. McLaughlin
Vallerie V. McLaughlin
Objective: Pulmonary arterial hypertension (PAH) affects up to 15% of patients with connective tissue diseases (CTDs). Previous recommendations developed as part of larger efforts in PAH did not include detailed recommendations for patients with CTD‐associated PAH. Therefore, we sought to develop recommendations for screening and early detection of CTD‐associated PAH.Methods: We performed a systematic review of the literature on the screening and diagnosis of PAH in CTD. Using the RAND/University of California, Los Angeles consensus methodology, we developed case scenarios followed by 2 stages of voting. First, international experts from a variety of specialties voted anonymously on the appropriateness of each case scenario. The experts then met face‐to‐face to discuss and resolve discrepant votes to arrive at consensus recommendations.Results: The key recommendation stated that all patients with systemic sclerosis (SSc) should be screened for PAH. In addition, patients with mixed connective tissue disease or other CTDs with scleroderma features (scleroderma spectrum disorders) should be screened for PAH. It was recommended that screening pulmonary function tests (PFTs) with single‐breath diffusing capacity for carbon monoxide, transthoracic echocardiogram, and measurement of N‐terminal pro–brain natriuretic peptide (NT‐proBNP) be performed in all patients with SSc and scleroderma spectrum disorders. In patients with SSc and scleroderma spectrum disorders, transthoracic echocardiogram and PFTs should be performed annually. The full screening panel (transthoracic echocardiogram, PFTs, and measurement of NT‐proBNP) should be performed as soon as any new signs or symptoms are present.Conclusion: We provide consensus‐based, evidence‐driven recommendations for screening and early detection of CTD‐associated PAH. It is our hope that these recommendations will lead to earlier detection of CTD‐associated PAH and ultimately improve patient outcomes.

25 July 2018 in BMJ Quality & Safety
Verified
Journal Article
Open access
PDF file
VVValerie M Vaughn
Valerie M Vaughn
SSSanjay Saint
Sanjay Saint
SKSarah L Krein
Sarah L Krein
JFJane H Forman
Jane H Forman
JMJennifer Meddings
Jennifer Meddings
VCVineet Chopra
Vineet Chopra
Background Identifying characteristics associated with struggling healthcare organisations may help inform improvement. Thus, we systematically reviewed the literature to: (1) Identify organisational factors associated with struggling healthcare organisations and (2) Summarise these factors into actionable domains. Methods Systematic review of qualitative studies that evaluated organisational characteristics of healthcare organisations that were struggling as defined by below-average patient outcomes (eg, mortality) or quality of care metrics (eg, Patient Safety Indicators). Searches were conducted in MEDLINE (via Ovid), EMBASE, Cochrane Library, CINAHL, and Web of Science from database inception through February 8 2018. Qualitative data were analysed using framework-based synthesis and summarised into key domains. Study quality was evaluated using the Critical Appraisal Skills Program tool. Results Thirty studies (33 articles) from multiple countries and settings (eg, acute care, outpatient) with a diverse range of interviewees (eg, nurses, leadership, staff) were included in the final analysis. Five domains characterised struggling healthcare organisations: poor organisational culture (limited ownership, not collaborative, hierarchical, with disconnected leadership), inadequate infrastructure (limited quality improvement, staffing, information technology or resources), lack of a cohesive mission (mission conflicts with other missions, is externally motivated, poorly defined or promotes mediocrity), system shocks (ie, events such as leadership turnover, new electronic health record system or organisational scandals that detract from daily operations), and dysfunctional external relations with other hospitals, stakeholders, or governing bodies. Conclusions Struggling healthcare organisations share characteristics that may affect their ability to provide optimal care. Understanding and identifying these characteristics may provide a first step to helping low performers address organisational challenges to improvement. Systematic review registration PROSPERO: CRD42017067367.

1 August 2014 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Closed access
PKPuja P. Khanna
Puja P. Khanna
HGHeather S. Gladue
Heather S. Gladue
MSManjit K. Singh
Manjit K. Singh
John FitzGeraldJohn FitzGerald
John FitzGerald
SBSangmee Bae
Sangmee Bae
DKDinesh Khanna
Dinesh Khanna

1 September 2017 in JAMA Neurology
Verified
Journal Article
Closed access
PDF file
MBMartin N. Bomalaski
Martin N. Bomalaski
ECEdward S. Claflin
Edward S. Claflin
WTWhitney Townsend
Whitney Townsend
MPMark Peterson
Mark Peterson
Importance Given its selective action on the ω1 subtype of the γ-aminobutyric acid A receptor, zolpidem tartrate presents a potential treatment mechanism for other neurologic disorders. Objective To synthesize studies that used zolpidem to treat neurologic disorders. Evidence Review Eligibility criteria included any published English-language article that examined the use of zolpidem for noninsomnia neurologic disorders in humans for all dates up to March 20, 2015. Searched databases included PubMed, Scopus, Web of Science Core Collection, the Cochrane Library, EMBASE, CENTRAL, and clinicaltrials.gov. Publication bias was mitigated by searching clinicaltrials.gov for unpublished studies. Two rounds of screening were performed based on title and then abstract, and coding was performed by 2 coders. All methods followed the PRISMA Reporting Guidelines for systematic reviews of the literature. Findings The initial search produced 2314 articles after removing duplicates. After exclusion based on a review of abstracts, 67 articles remained for full manuscript review. Thirty-one studies treated movement disorders, 22 treated disorders of consciousness, and 14 treated other neurologic conditions, including stroke, traumatic brain injury, encephalopathy, and dementia. Study designs included case reports (n = 28), case series (n = 8), single-patient interventional (n = 13), pretest and posttest (n = 9), randomized clinical trials (n = 9), and crossover studies (n = 5). Only 11 studies had more than 10 participants. Effects of zolpidem were wide ranging (eg, improvement on the JFK Coma Recovery Scale–Revised, the Unified Parkinson Disease Rating Scale, and the Burke-Fahn-Marsden Dystonia Rating Scale) and generally lasted 1 to 4 hours before the participant returned to baseline. Sedation was the most common adverse effect. Conclusions and Relevance Zolpidem has been observed to transiently treat a large variety of neurologic disorders, most often related to movement disorders and disorders of consciousness. Much of what is known comes from case reports and small interventional trials. These findings may represent a new treatment mechanism for these disorders.

14 April 2017 in Arthroscopy
Verified
Journal Article
Closed access
JKJacob M. Kirsch
Jacob M. Kirsch
JTJared R. Thomas
Jared R. Thomas
MKMoin Khan
Moin Khan
WTWhitney A. Townsend
Whitney A. Townsend
JLJeffrey N. Lawton
Jeffrey N. Lawton
ABAsheesh Bedi
Asheesh Bedi